Association between autophagy and KRAS mutation with clinicopathological variables in colorectal cancer patients

被引:0
作者
Awi, Noel Jacques [1 ]
Yap, Hooi-Yeen [1 ]
Armon, Subasri [2 ]
Low, John Seng-Hooi [3 ]
Peh, Kaik-Boo [4 ]
Peh, Suat-Cheng [1 ,3 ]
Lee, C. Soon [5 ]
Teow, Sin-Yeang [1 ]
机构
[1] Sunway Univ, Dept Med Sci, Sch Med & Life Sci, Jalan Univ, Subang Jaya 47500, Selangor Darul, Malaysia
[2] Hosp Kuala Lumpur, Pathol Dept, Jalan Pahang, Kuala Lumpur 50586, Malaysia
[3] Sunway Med Ctr, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor Darul, Malaysia
[4] Mahkota Med Ctr, Jalan Merdeka, Melaka 75000, Malaysia
[5] Western Sydney Univ, Sch Med, Discipline Pathol, Sydney, NSW, Australia
关键词
Autophagy proteins; KRAS mutation; prognosis; Malaysian; Indonesian; LC3A; LC3B; p62; colorectal cancer; KIRSTEN RAS MUTATIONS; POOR-PROGNOSIS; BIOMARKERS; CELLS;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Autophagy is a host defensive mechanism responsible for eliminating harmful cellular components through lysosomal degradation. Autophagy has been known to either promote or suppress various cancers including colorectal cancer (CRC). KRAS mutation serves as an important predictive marker for epidermal growth factor receptor (EGFR)-targeted therapies in CRC. However, the relationship between autophagy and KRAS mutation in CRC is not well-studied. In this single-centre study, 92 formalin-fixed paraffin-embedded (PIPE) tissues of CRC patients (42 Malaysian Chinese and 50 Indonesian) were collected and KRAS mutational status was determined by quantitative PCR (qPCR) (n=92) while the expression of autophagy effector (p62, LC3A and LC3B) was examined by immunohistochemistry (II-IC) (n=48). The outcomes of each were then associated with the clinicopathological variables (n=48). Our findings demonstrated that the female CRC patients have a higher tendency in developing KRAS mutation in the Malaysian Chinese population (p<0.05). Expression of autophagy effector LC3A was highly associated with the tumour grade in CRC (p<0.001) but not with other clinicopathological parameters. Lastly, the survival analysis did not yield a statistically significant outcome. Overall, this small cohort study concluded that KRAS mutation and autophagy effectors are not good prognostic markers for CRC patients.
引用
收藏
页码:269 / 279
页数:11
相关论文
共 29 条
[21]   Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities [J].
Porru, Manuela ;
Pompili, Luca ;
Caruso, Carla ;
Biroccio, Annamaria ;
Leonetti, Carlo .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
[22]   Association between clinicopathological characteristics and RAS mutation in colorectal cancer [J].
Rimbert, Johan ;
Tachon, Gaelle ;
Junca, Audelaure ;
Villalva, Claire ;
Karayan-Tapon, Lucie ;
Tougeron, David .
MODERN PATHOLOGY, 2018, 31 (03) :517-526
[23]   Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation [J].
Sato, Kazunori ;
Tsuchihara, Katsuya ;
Fujii, Satoshi ;
Sugiyama, Masanori ;
Goya, Tomoyuki ;
Atomi, Yutaka ;
Ueno, Takashi ;
Ochiai, Atsushi ;
Esumi, Hiroyasu .
CANCER RESEARCH, 2007, 67 (20) :9677-9684
[24]   Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status [J].
Schmitz, Klaus Juergen ;
Ademi, Ceflije ;
Bertram, Stefanie ;
Schmid, Kurt Werner ;
Baba, Hideo Andreas .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
[25]   Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology [J].
Sepulveda, Antonia R. ;
Hamilton, Stanley R. ;
Allegra, Carmen J. ;
Grody, Wayne ;
Cushman-Vokoun, Allison M. ;
Funkhouser, William K. ;
Kopetz, Scott E. ;
Lieu, Christopher ;
Lindor, Noralane M. ;
Minsky, Bruce D. ;
Monzon, Federico A. ;
Sargent, Daniel J. ;
Singh, Veena M. ;
Willis, Joseph ;
Clark, Jennifer ;
Colasacco, Carol ;
Rumble, R. Bryan ;
Temple-Smolkin, Robyn ;
Ventura, Christina B. ;
Nowak, Jan A. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) :1453-+
[26]   CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer [J].
Smeby, J. ;
Sveen, A. ;
Merok, M. A. ;
Danielsen, S. A. ;
Eilertsen, A. ;
Guren, M. G. ;
Dienstmann, R. ;
Nesbakken, A. ;
Lothe, R. A. .
ANNALS OF ONCOLOGY, 2018, 29 (05) :1227-1234
[27]   Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers [J].
Yang, Qiwei ;
Huo, Sibo ;
Sui, Yujie ;
Du, Zhenwu ;
Zhao, Haiyue ;
Liu, Yu ;
Li, Wei ;
Wan, Xin ;
Liu, Tongjun ;
Zhang, Guizhen .
FRONTIERS IN ONCOLOGY, 2018, 8
[28]  
Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
[29]   Cytoplasmic SQSTM1/P62 Accumulation Predicates a Poor Prognosis in Patients with Malignant Tumor [J].
Zhu, Linhai ;
Wang, Yiqing ;
He, Jing ;
Tang, Jie ;
Lv, Wang ;
Hu, Jian .
JOURNAL OF CANCER, 2018, 9 (21) :4072-4086